Latest Conference

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.

New research highlights lumateperone's effectiveness as an adjunctive treatment for major depressive disorder, improving depressive symptoms and sexual function.

New phase 3 data highlights seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting primary end points. Andrew J. Cutler, MD, shares his thoughts.

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.

New analysis reveals Ingrezza achieves rapid symptomatic remission in tardive dyskinesia, enhancing patient quality of life and reducing disease burden.

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

New study shows lumateperone (Caplyta) significantly improves symptoms in major depressive disorder with anxious distress, offering hope for treatment-resistant patients.

Half of patients with stuttering also experience anxiety, highlighting the psychiatrist’s role in care and support.

Because stuttering represents a spectrum disorder, a spectrum of treatments are needed.

Shahriar SheikhBahaei, PhD, discusses how animal models may lead to better treatments.

Shahriar SheikhBahaei, PhD, shares insights into the neurobiology of stuttering at STARS conference.

Gerald A. Maguire, MD, details the unmet needs in stuttering at the inaugural conference.

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

Roche unveils promising Alzheimer disease treatments and diagnostic tools, including trontinemab and the Elecsys pTau217 blood test, at the AAIC conference.

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Dr Jonathan Meyer highlights effective VMAT 2 inhibitors for tardive dyskinesia treatment, emphasizing tailored approaches for improved patient outcomes.

Innovative approaches enhance understanding of tardive dyskinesia's impact on patients' lives, shifting focus from detection to functional well-being.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

Clinician discusses the importance of maximizing medication doses and trial periods for effectively managing tardive dyskinesia at the Southern California Psychiatry Conference.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.